A Phase IB, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination With GDC-0973 When Administered in BRAFV600E Mutation-Positive Patients Previously Treated (But Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally- Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed After Treatment With Vemurafenib

Inclusion Criteria:

- Adult patients, age >/=18 years

- Patients with histologically confirmed metastatic melanoma (unresectable Stage IIIc
and Stage IV, American Joint Committee on Cancer (AJCC) metastatic melanoma)

- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

- Eastern Cooperative Oncology Group (ECOG) Performance Status of
- Patients must

1. be previously untreated for locally advanced/unresectable or metastatic melanoma
or

2. previously treated but without prior exposure to any BRAF or MEK inhibitor
therapy or

3. progressed on vemurafenib while participating in a Phase I (including clinical
pharmacology studies), II, or III clinical study or EAP immediately prior to
enrollment in this study or

4. progressed on vemurafenib administered in a postmarketing setting immediately
prior to enrollment in this study.

- Life expectancy >/=12 weeks

Exclusion Criteria:

- History of prior significant toxicity from another RAF or MEK pathway inhibitor
requiring discontinuation of treatment

- Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment

- Experimental therapy within 4 weeks prior to first dose of study drug treatment
except vemurafenib

- Major surgery within 4 weeks of first dose of study drug treatment or planning a
major surgery during the study